GLP-1 receptor agonist promotes brown remodelling in mouse white adipose tissue through SIRT1

详细信息    查看全文

• 作者：Fen Xu ; Beisi Lin ; Xiaobin Zheng ; Zonglan Chen ; Huanyi Cao ; Haixia Xu…
• 关键词：Adipocytes ; Fatty acid oxidation ; GLP ; 1 ; Lipolysis ; Obesity ; Sirtuin 1
• 刊名：Diabetologia
• 出版年：2016
• 出版时间：May 2016
• 年：2016
• 卷：59
• 期：5
• 页码：1059-1069
• 全文大小：998 KB
• 参考文献：1.Twig G, Afek A, Derazne E et al (2014) Diabetes risk among overweight and obese metabolically healthy young adults. Diabetes Care 37:2989–2995CrossRef PubMed
  2.Astrup A, Rossner S, Van Gaal L et al (2009) Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 374:1606–1616CrossRef PubMed
  3.DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD (2005) Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28:1092–1100CrossRef PubMed
  4.Kanoski SE, Fortin SM, Arnold M, Grill HJ, Hayes MR (2011) Peripheral and central GLP-1 receptor populations mediate the anorectic effects of peripherally administered GLP-1 receptor agonists, liraglutide and exendin-4. Endocrinology 152:3103–3112CrossRef PubMed PubMedCentral
  5.Wettergren A, Wojdemann M, Holst JJ (1998) Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow. Am J Physiol 275:G984–G992PubMed
  6.Nielsen TS, Jessen N, Jorgensen JO, Moller N, Lund S (2014) Dissecting adipose tissue lipolysis: molecular regulation and implications for metabolic disease. J Mol Endocrinol 52:R199–R222CrossRef PubMed
  7.Wilson-Fritch L, Nicoloro S, Chouinard M et al (2004) Mitochondrial remodeling in adipose tissue associated with obesity and treatment with rosiglitazone. J Clin Invest 114:1281–1289CrossRef PubMed PubMedCentral
  8.Yin X, Lanza IR, Swain JM, Sarr MG, Nair KS, Jensen MD (2014) Adipocyte mitochondrial function is reduced in human obesity independent of fat cell size. J Clin Endocrinol Metab 99:E209–E216CrossRef PubMed PubMedCentral
  9.Cannon B, Nedergaard J (2004) Brown adipose tissue: function and physiological significance. Physiol Rev 84:277–359CrossRef PubMed
  10.Bartelt A, Heeren J (2014) Adipose tissue browning and metabolic health. Nat Rev Endocrinol 10:24–36CrossRef PubMed
  11.Wu J, Cohen P, Spiegelman BM (2013) Adaptive thermogenesis in adipocytes: is beige the new brown? Genes Dev 27:234–250CrossRef PubMed PubMedCentral
  12.Feige JN, Lagouge M, Canto C et al (2008) Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation. Cell Metab 8:347–358CrossRef PubMed
  13.Milne JC, Lambert PD, Schenk S et al (2007) Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 450:712–716CrossRef PubMed PubMedCentral
  14.Chakrabarti P, English T, Karki S et al (2011) SIRT1 controls lipolysis in adipocytes via FOXO1-mediated expression of ATGL. J Lipid Res 52:1693–1701CrossRef PubMed PubMedCentral
  15.Xu C, Bai B, Fan P et al (2013) Selective overexpression of human SIRT1 in adipose tissue enhances energy homeostasis and prevents the deterioration of insulin sensitivity with ageing in mice. Am J Transl Res 5:412–426PubMed PubMedCentral
  16.Xu F, Gao Z, Zhang J et al (2010) Lack of SIRT1 (mammalian sirtuin 1) activity leads to liver steatosis in the SIRT1 +/- mice: a role of lipid mobilization and inflammation. Endocrinology 151(6):2504–2514CrossRef PubMed PubMedCentral
  17.Cheng HL, Mostoslavsky R, Saito S et al (2003) Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc Natl Acad Sci U S A 100(19):10794–10799CrossRef PubMed PubMedCentral
  18.Xu F, Li Z, Zheng X et al (2014) SIRT1 mediates the effect of GLP-1 receptor agonist exenatide on ameliorating hepatic steatosis. Diabetes 63:3637–3646CrossRef PubMed
  19.Anil KK, Marita AR (2000) Troglitazone prevents and reverses dexamethasone induced insulin resistance on glycogen synthesis in 3T3 adipocytes. Br J Pharmacol 130:351–358CrossRef
  20.Jendle J, Nauck MA, Matthews DR et al (2009) Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab 11:1163–1172CrossRef PubMed
  21.Richard JE, Anderberg RH, Goteson A, Gribble FM, Reimann F, Skibicka KP (2015) Activation of the GLP-1 receptors in the nucleus of the solitary tract reduces food reward behavior and targets the mesolimbic system. PLoS One 10, e119034
  22.van Bloemendaal L, IJzerman RG, Ten KJ et al (2014) GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans. Diabetes 63:4186–4196CrossRef PubMed
  23.Wei Q, Li L, Chen JA, Wang SH, Sun ZL (2015) Exendin-4 improves thermogenic capacity by regulating fat metabolism on brown adipose tissue in mice with diet-induced obesity. Ann Clin Lab Sci 45:158–165PubMed
  24.Vendrell J, El BR, Peral B et al (2011) Study of the potential association of adipose tissue GLP-1 receptor with obesity and insulin resistance. Endocrinology 152:4072–4079CrossRef PubMed
  25.Bertin E, Arner P, Bolinder J, Hagstrom-Toft E (2001) Action of glucagon and glucagon-like peptide-1-(7-36) amide on lipolysis in human subcutaneous adipose tissue and skeletal muscle in vivo. J Clin Endocrinol Metab 86:1229–1234PubMed
  26.Bi Y, Zhang B, Xu W et al (2014) Effects of exenatide, insulin, and pioglitazone on liver fat content and body fat distributions in drug-naive subjects with type 2 diabetes. Acta Diabetol 51:865–873CrossRef PubMed
  27.Gaidhu MP, Fediuc S, Anthony NM et al (2009) Prolonged AICAR-induced AMP-kinase activation promotes energy dissipation in white adipocytes: novel mechanisms integrating HSL and ATGL. J Lipid Res 50:704–715CrossRef PubMed PubMedCentral
  28.Ceddia RB (2013) The role of AMP-activated protein kinase in regulating white adipose tissue metabolism. Mol Cell Endocrinol 366:194–203CrossRef PubMed
  29.Um JH, Park SJ, Kang H et al (2010) AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes 59:554–563CrossRef PubMed PubMedCentral
  30.Jun HJ, Joshi Y, Patil Y, Noland RC, Chang JS (2014) NT-PGC-1alpha activation attenuates high-fat diet-induced obesity by enhancing brown fat thermogenesis and adipose tissue oxidative metabolism. Diabetes 63:3615–3625CrossRef PubMed PubMedCentral
  31.Qiang L, Wang L, Kon N et al (2012) Brown remodeling of white adipose tissue by SirT1-dependent deacetylation of Ppargamma. Cell 150:620–632CrossRef PubMed PubMedCentral
  32.Barbatelli G, Murano I, Madsen L et al (2010) The emergence of cold-induced brown adipocytes in mouse white fat depots is determined predominantly by white to brown adipocyte transdifferentiation. Am J Physiol Endocrinol Metab 298:E1244–E1253CrossRef PubMed
  33.Andrade JM, Frade AC, Guimaraes JB et al (2014) Resveratrol increases brown adipose tissue thermogenesis markers by increasing SIRT1 and energy expenditure and decreasing fat accumulation in adipose tissue of mice fed a standard diet. Eur J Nutr 53:1503–1510CrossRef PubMed
  34.Mercader J, Palou A, Bonet ML (2011) Resveratrol enhances fatty acid oxidation capacity and reduces resistin and retinol-binding protein 4 expression in white adipocytes. J Nutr Biochem 22:828–834CrossRef PubMed
  35.Boschmann M, Engeli S, Dobberstein K et al (2009) Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients. J Clin Endocrinol Metab 94:846–852CrossRef PubMed
  36.Nogueiras R, Perez-Tilve D, Veyrat-Durebex C et al (2009) Direct control of peripheral lipid deposition by CNS GLP-1 receptor signaling is mediated by the sympathetic nervous system and blunted in diet-induced obesity. J Neurosci 29:5916–5925CrossRef PubMed
  37.Beiroa D, Imbernon M, Gallego R et al (2014) GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK. Diabetes 63:3346–3358CrossRef PubMed
  38.Kooijman S, Wang Y, Parlevliet ET et al (2015) Central GLP-1 receptor signalling accelerates plasma clearance of triacylglycerol and glucose by activating brown adipose tissue in mice. Diabetologia 58:2637–2646CrossRef PubMed PubMedCentral
  39.van Bloemendaal L, Ten Kulve JS, la Fleur SE et al (2014) Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. J Endocrinol 221(1):T1–T16CrossRef PubMed
  40.Heppner KM, Marks S, Holland J et al (2015) Contribution of brown adipose tissue activity to the control of energy balance by GLP-1 receptor signalling in mice. Diabetologia 58:2124–2132CrossRef PubMed
  
• 作者单位：Fen Xu (1) (2)
  Beisi Lin (1) (2)
  Xiaobin Zheng (1) (2)
  Zonglan Chen (1) (2)
  Huanyi Cao (1) (2)
  Haixia Xu (1) (2)
  Hua Liang (1) (2)
  Jianping Weng (1) (2)
  
  1. Department of Endocrinology and Metabolism, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, 510630, People’s Republic of China
  2. Guangdong Provincial Key Laboratory of Diabetology, Guangzhou, People’s Republic of China
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Internal Medicine
  Metabolic Diseases
  Human Physiology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1432-0428

文摘

Aims/hypothesis Accumulating evidence has revealed the significant role of glucagon-like peptide-1 (GLP-1) in weight loss. Sirtuin 1 (SIRT1) plays a vital role in the regulation of lipid metabolism. Here, we investigated the contribution of lipolytic and oxidative changes in white adipose tissue (WAT) to the weight-lowering effect induced by the GLP-1 receptor (GLP-1R) agonist exenatide (exendin-4) in mice. We also looked at the role of SIRT1 in this process.